PMID: 6161534Jan 1, 1981Paper

Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide

The American Journal of Cardiology
R A WinkleF A Peters

Abstract

Eleven patients with chronic ventricular arrhythmias took part in a study of N-acetylprocainamide (NAPA), the major metabolite of procainamide, in order to characterize further NAPA's clinical pharmacology and antiarrhythmic action. The frequency of ventricular arrhythmia on 24 hour ambulatory electrocardiographic recordings was comparable on recordings obtained in a prestudy screening, during treatment with placebo before administration of NAPA and after treatment with NAPA. The initial dosage of NAPA was 500 mg every 8 hours, which was increased by 500 mg increments every few days until 90 percent suppression of arrhythmia or intolerable adverse effects occurred. Only two patients achieved 90 percent suppression of ventricular ectopic complexes. The mean plasma concentration associated with 90 percent suppression of arrhythmia in these two patients ws 12.6 and 32.3 mg/ml, respectively. One of these two patients was unable to continue long-term therapy with NAPA because of a rash. Other adverse effects included gastrointestinal symptoms in seven patients with visual symptoms in four patients at plasma concentratons as low as 6.9 mg/ml. NAPA obeyed linear pharmacokinetics over the range of dosages studied (500 to 2,500 mg every...Continue Reading

Citations

Apr 1, 1982·American Heart Journal·R L WoosleyJ A Oates
Feb 1, 1985·American Heart Journal·D M Roden, R L Woosley
Jan 1, 1986·Journal of the American College of Cardiology·V TorresJ C Somberg
Nov 1, 1989·Medical Toxicology and Adverse Drug Experience·F A Fish, D M Roden
Dec 5, 1989·The American Journal of Cardiology·P Jaillon, M Drici
May 1, 1981·The American Journal of Cardiology·P JaillonR A Winkle
Sep 22, 1983·The American Journal of Cardiology·R E Kates
Aug 26, 1993·The American Journal of Cardiology·D M Roden
Jul 1, 1985·Pacing and Clinical Electrophysiology : PACE·W G Stevenson, J Weiss
Dec 1, 1982·The American Journal of Medicine·S C Vlay, P R Reid
Jan 1, 1984·Annals of the New York Academy of Sciences·E G Giardina
Apr 1, 1983·Drug Intelligence & Clinical Pharmacy·M B BottorffR L Batenhorst

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.